Literature DB >> 6798136

Lipopolysaccharide and high-molecular-weight polysaccharide serotypes of Pseudomonas aeruginosa.

G B Pier, D M Thomas.   

Abstract

The serotype distribution of bacteremic and nonbacteremic clinical isolates of Pseudomonas aeruginosa in relation to the Fisher immunotyping scheme, the International Antigenic Typing System (IATS), and high-molecular-weight polysaccharide determinants was investigated. Of 281 bacteremic isolates, 273 (97.2%) were serotyped by one of the seven IATS specificities that correspond to a Fisher lipopolysaccharide/high-molecular-weight polysaccharide specificity. In contrast, these seven serotypes accounted for only 68.5% of the 124 nonbacteremic clinical isolates. Review of the reported serotype distribution of P. aeruginosa isolates in Europe further supported the finding of a limited serotype distribution among bacteremic clinical isolates. Fifteen of the 17 IATS serotypes were found among all of the strains of P. aeruginosa serotyped, an indication that most of the IATS serotypes are present in the United States. Thus, only certain lipopolysaccharide immunotypes of P. aeruginosa occur as clinical bacteremic isolates, and a multivalent, high-molecular-weight polysaccharide vaccine directed at the lipopolysaccharide type determinants of P. aeruginosa has potential usefulness.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6798136     DOI: 10.1093/infdis/145.2.217

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  32 in total

1.  Bacterial lipopolysaccharide (LPS)-specific antibodies in commercial human immunoglobulin preparations: superior antibody content of an IgM-enriched product.

Authors:  M Trautmann; T K Held; M Susa; M A Karajan; A Wulf; A S Cross; R Marre
Journal:  Clin Exp Immunol       Date:  1998-01       Impact factor: 4.330

2.  Antibiograms, serotypes, and plasmid profiles of Pseudomonas aeruginosa associated with corneal ulcers and contact lens wear.

Authors:  M S Mayo; W L Cook; R L Schlitzer; M A Ward; L A Wilson; D G Ahearn
Journal:  J Clin Microbiol       Date:  1986-09       Impact factor: 5.948

3.  Use of a pilin gene probe to study molecular epidemiology of Pseudomonas aeruginosa.

Authors:  D P Speert; M E Campbell; S W Farmer; K Volpel; A M Joffe; W Paranchych
Journal:  J Clin Microbiol       Date:  1989-11       Impact factor: 5.948

4.  Functionally active monoclonal antibody that recognizes an epitope on the O side chain of Pseudomonas aeruginosa immunotype-1 lipopolysaccharide.

Authors:  B J Stoll; M Pollack; L S Young; N Koles; R Gascon; G B Pier
Journal:  Infect Immun       Date:  1986-09       Impact factor: 3.441

5.  Pseudomonas aeruginosa immunotype 5 polysaccharide-toxin A conjugate vaccine.

Authors:  S J Cryz; E Furer; J C Sadoff; R Germanier
Journal:  Infect Immun       Date:  1986-04       Impact factor: 3.441

6.  Seroepidemiology of Klebsiella bacteremic isolates and implications for vaccine development.

Authors:  S J Cryz; P M Mortimer; V Mansfield; R Germanier
Journal:  J Clin Microbiol       Date:  1986-04       Impact factor: 5.948

7.  Immunization with Pseudomonas aeruginosa high-molecular-weight polysaccharides prevents death from Pseudomonas burn infections in mice.

Authors:  M Pollack; G B Pier; R K Prescott
Journal:  Infect Immun       Date:  1984-02       Impact factor: 3.441

8.  Pseudomonas aeruginosa lipopolysaccharide: evidence that the O side chains and common antigens are on the same molecule.

Authors:  K Hatano; J B Goldberg; G B Pier
Journal:  J Bacteriol       Date:  1993-08       Impact factor: 3.490

9.  Avirulence of a Pseudomonas aeruginosa algC mutant in a burned-mouse model of infection.

Authors:  J B Goldberg; M J Coyne; A N Neely; I A Holder
Journal:  Infect Immun       Date:  1995-10       Impact factor: 3.441

10.  Pseudomonas aeruginosa isolates from patients with cystic fibrosis: a class of serum-sensitive, nontypable strains deficient in lipopolysaccharide O side chains.

Authors:  R E Hancock; L M Mutharia; L Chan; R P Darveau; D P Speert; G B Pier
Journal:  Infect Immun       Date:  1983-10       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.